| Patient | Charles Darwin |
|---|---|
| Date of birth | 1986-02-12 |
| Identifiers | MRN HR-NI003-SYN; SSN (made up) 000-03-2967 |
| Document date | 2026-06-09 |
| Author | Bernard Ashworth, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three-month review of cyclic vomiting syndrome on amitriptyline. [S]
Mr. Darwin returns eight weeks after starting amitriptyline. The dose was raised to 50 mg after two weeks and to 75 mg four weeks ago, by portal message. He had one episode two weeks into treatment; he took the sumatriptan spray and an ondansetron tablet within half an hour of the prodrome, and it settled in about ten hours without emergency care. He has had no episode in the four weeks since reaching 75 mg, and his cold three weeks ago passed without one. He has a dry mouth, mild constipation, and some grogginess in the first hour of the morning, and has gained 1 kg. He has no dizziness on standing, palpitations outside the prodrome, or urinary hesitancy. He practices the relaxation breathing most evenings and has not yet started cognitive behavioral therapy. No ECG was done at the 50 mg step, because the increase was made by portal message. [S]
| Element | Detail |
|---|---|
| Medicine | Amitriptyline 75 mg at bedtime for four weeks |
| Episodes | One in eight weeks, aborted at the prodrome; none at 75 mg |
| Side effects | Dry mouth, mild constipation, morning grogginess; weight up 1 kg |
| Self-management | Relaxation breathing most evenings; trigger plan followed |
| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Positive | Mild constipation; no vomiting in four weeks |
| Ears, nose, mouth, and throat | Positive | Dry mouth |
| Cardiovascular | Negative | No palpitations, chest pain, or fainting |
| Neurological | Positive | Grogginess in the first hour of the morning; no dizziness on standing |
| Psychiatric | Negative | Mood steady; less worried about going out; no thoughts of self-harm |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Amitriptyline 25 mg oral tablet, one tablet at bedtime | One tablet by mouth at bedtime | Oral route | 2026-04-14 to 2026-04-28 | completed | S |
| Amitriptyline 50 mg oral tablet, one tablet at bedtime | One tablet by mouth at bedtime | Oral route | 2026-04-28 to 2026-05-12 | completed | S |
| Amitriptyline 75 mg oral tablet, one tablet at bedtime | One tablet by mouth at bedtime | Oral route | 2026-05-12 | active | S |
| Sumatriptan 20 mg nasal spray, one spray at the first sign of an episode | One spray in one nostril at the start of the prodrome; may repeat once after 2 hours; no more than 2 sprays a day or 6 a week | Nasal route | 2026-04-14 | active | S |
| Ondansetron 8 mg orally disintegrating tablet at the first sign of an episode | Dissolve one tablet on the tongue at the start of the prodrome, then every 8 hours as needed during an episode | Oral route | 2026-04-14 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-09 | Body height | 183 | cm | S |
| 2026-06-09 | Body weight | 72.4 | kg | S |
| 2026-06-09 | Body mass index (BMI) [Ratio] | 21.6 | kg/m2 | S |
| 2026-06-09 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-06-09 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-06-09 | Heart rate | 72 | /min | S |
| 2026-06-09 | Respiratory rate | 14 | /min | S |
| 2026-06-09 | Body temperature | 36.6 | Cel | S |
| 2026-06-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-09 | Q-T interval corrected | 436 | ms | <=450 ms | Normal | S |
| 2026-06-09 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 6 | {score} | S | ||
| 2026-06-09 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S |
Vital signs recorded on 2026-06-09; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 72.4 kg |
| Cardiovascular | Regular rhythm at 72 per minute; blood pressure 118/74 mmHg, with no drop on standing |
| Abdomen | Soft and non-tender |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Cyclic vomiting syndrome, moderate to severe, meeting Rome IV criteria after a normal work-up; provisional clinical diagnosis | active | provisional | R11.15 | S — Synthetic provisional diagnosis at the gastroenterology consultation, anchored to his documented episodic vomiting. It is clinical, with no confirmatory test, and does not confirm any historical theory. |
| Recurrent episodes of nausea and vomiting over more than a year, with prodromal trembling, palpitations, and dizziness, and flatulence and fatigue between episodes; cause under evaluation | resolved | confirmed | R11.2 | S — Synthetic presenting concern at the index visit, superseded by the provisional diagnosis at the six-week visit; the episodic vomiting is documented (D). |
| Common cold, without a vomiting episode; resolved | resolved | confirmed | J00 | S — Synthetic intercurrent illness at an unscheduled visit; chosen because infection is a common trigger of cyclic vomiting and because cold medicines interact with amitriptyline. It does not echo a documented illness. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Self-management | Episode diary: number, length, and severity of episodes, prodrome, emergency visits, and missed work | Every visit | Completed today | One episode in eight weeks, about ten hours, aborted at the prodrome; none in four weeks at 75 mg |
| Examination | Rome IV criteria and red flags (vomiting between episodes, weight loss, nocturnal pain, neurological signs, onset after 50) | At diagnosis and with any change in pattern | Completed today | Pattern unchanged; no red flags |
| Laboratory | Blood count, electrolytes and glucose, liver panel, lipase, urinalysis, TSH, cortisol, celiac serology | At diagnosis between episodes; repeat only for an atypical episode | Up to date | Normal at diagnosis; no atypical episode to prompt a repeat |
| Imaging | Upper endoscopy and small-bowel imaging (CT enterography) | Once at diagnosis | Up to date | Normal at diagnosis; no repeat needed |
| Imaging | Gastric emptying study | Not routine; only between episodes when gastroparesis is suspected | Not indicated | No symptoms of gastroparesis |
| Medication safety | ECG with QTc on amitriptyline and ondansetron (below 450 ms in men) | Baseline, at about 50 mg during titration, and at the target dose | Deferred | The ECG due at about 50 mg was not done, a deviation from the guideline: the dose was raised by portal message without an ECG order. Judging by today's tracing at 75 mg (QTc 436 ms, sinus rhythm), no harm resulted. Corrective action: dose changes are now made at a visit or with an ECG ordered at the same time |
| Medication safety | ECG with QTc on amitriptyline and ondansetron (below 450 ms in men) | Baseline, at about 50 mg during titration, and at the target dose | Completed today | QTc 436 ms at the target dose of 75 mg, up from 412 ms at baseline and below 450 ms; sinus rhythm at 72 |
| Medication safety | Amitriptyline tolerability: drowsiness, dry mouth, constipation, dizziness on standing, weight | Each visit on treatment | Completed today | Dry mouth, mild constipation, morning grogginess; weight 72.4 kg (up 1.0 kg); no dizziness on standing |
| Survey | Mood and thoughts of self-harm on a tricyclic (PHQ-9) | Each visit on treatment | Completed today | PHQ-9 4, with item 9 scored 0 |
| Survey | Anxiety screen (GAD-7) | At diagnosis, then every three months | Completed today | GAD-7 6, down from 8 |
| Medication safety | Abortive plan: timing and response to sumatriptan nasal spray and ondansetron, and dose limits | Every visit | Completed today | Used once, within half an hour of the prodrome, with the episode settling in about ten hours; within dose limits |
| Self-management | Individualized emergency department protocol letter | At diagnosis; update with any change in treatment | Up to date | Letter carried; not needed |
| Self-management | Triggers: sleep, meals, travel, social stress, infections | Every visit | Completed today | Regular meals and sleep kept; a cold three weeks ago passed without an episode |
| Self-management | Cannabis and other substance use, and hot-bathing behavior (cannabinoid hyperemesis syndrome) | At diagnosis and yearly | Up to date | No cannabis use |
| Examination | Comorbidities: migraine, orthostatic and autonomic symptoms, sleep disorders | At diagnosis and yearly | Up to date | No migraine or orthostatic symptoms; sleep regular |
| Medication safety | Mitochondrial supplements (coenzyme Q10, riboflavin) | Conditional; consider with a partial response | Not indicated | Early response to amitriptyline; reconsider only if the response becomes partial |
| Medication safety | Alternative prophylaxis (topiramate or aprepitant) | Only if amitriptyline fails or is not tolerated | Not indicated | Amitriptyline effective and tolerated |
| Self-management | Relaxation training, meditation, or biofeedback; cognitive behavioral therapy offered | Ongoing | Completed today | Breathing practice most evenings; cognitive behavioral therapy still offered |
| Examination | Weight and hydration | Every visit | Completed today | 72.4 kg; well hydrated |
Goal progress:
Guideline basis: Guidelines on management of cyclic vomiting syndrome in adults by the American Neurogastroenterology and Motility Society and the Cyclic Vomiting Syndrome Association (2019); Anxiety Disorders in Adults: Screening (2023)
Follow-up: Preventive health visit in about six weeks. Six-month review in three months, after three months at the target dose. Next scheduled visit 2026-07-21: preventive health visit. [S]